Infusion Laboratory: Protocol 3 (Risperidone) - 4
Phase 1
- Conditions
- Cocaine-Related Disorders
- Registration Number
- NCT00000339
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Brief Summary
The purpose of this study is to evaluate clinical safety issues pertaining to risperidone, to cocaine and to its interaction, and to determine how pretreatment with risperidone modifies the subjective as well as physiological effects of cocaine.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 13
Inclusion Criteria
M/F ages 21-50. Meet DSM-IV criteria for cocaine dependence. Agree to conditions of the study and sign informed consent.
Exclusion Criteria
Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nuring women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics. Acute hepatitis. Other medical condtions that deem participation to be unsafe.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method Clinical physiological response to cocaine challen Degree to which study medication influences change Evidence of change in neurotoxicity based on chore Degree of drug craving History, incidence and amount of drug use Type and severity of stimulant withdrawal symptoms Characterization of study population Population incidence of symptoms of depression, po Frequency and intensity of drug use and sexual beh Evidence of change in subjective responses to coca
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Friends Research Institute
🇺🇸Los Angeles, California, United States